human F8 protein

RefSeq NM_000132

Also Known As:

F8 protein, human; BAY 81-8973; Bioclate; F8B protein, human; FVIII protein, human; Hemofil; Hemofil HM; Hemofil M; Hemophil; Humate-P; Kogenate; Kogenate FS; Kovaltry; Monoclate; Recombinate; antihemophilic factor human; coagulation factor VIII, human; coagulation factor VIII, procoagulant component (hemophilia A) protein, human; factor VIII, human; octocog alfa; xyntha

Networked: 153 relevant articles (19 outcomes, 48 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Church, Nikki: 5 articles (06/2020 - 01/2016)
2.	Maas Enriquez, M: 5 articles (09/2016 - 03/2015)
3.	Pasca, Samantha: 4 articles (06/2022 - 07/2018)
4.	Zanon, Ezio: 4 articles (06/2022 - 07/2018)
5.	Chen, Zhenping: 4 articles (02/2022 - 01/2021)
6.	Wu, Runhui: 4 articles (02/2022 - 01/2021)
7.	Beckmann, H: 4 articles (09/2016 - 03/2015)
8.	Gill, J C: 4 articles (09/2016 - 01/2004)
9.	Oldenburg, J: 4 articles (09/2016 - 01/2013)
10.	Tseneklidou-Stoeter, D: 4 articles (09/2016 - 03/2015)

Related Diseases

1.	Hemophilia A (Haemophilia) 11/01/2016 - "Improved pharmacokinetics and no effect on safety of BAY 81-8973 were observed in clinical trials in patients with hemophilia A." 05/01/2016 - "BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial." 06/01/2020 - "BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years." 05/01/2016 - "Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme." 01/01/2023 - "LEOPOLD I Part B (NCT01029340) and LEOPOLD Kids Part A (NCT01311648) were octocog alfa Phase 3, multinational, open-label studies in patients with severe hemophilia A aged 12-65 years and ≤12 years, respectively. "
2.	Hemorrhage 11/01/2003 - "This study supports the safety and efficacy of Humate-P administered in doses calculated in VWF:RCo units for the treatment of urgent bleeding episodes in patients with VWD." 01/01/2021 - "This study compared the efficacy and consumption of rVIII-SingleChain (lonoctocog alfa, AFSTYLA®) with rAHF-PFM (octocog alfa, Advate®) and rFVIIIFc (efmoroctocog alfa, Elocta®), for the prophylaxis and treatment of bleeding episodes in previously treated adolescents/adults with severe haemophilia A, through a matching-adjusted indirect comparison (MAIC). " 03/01/2016 - "Pharmacodynamics study revealed comparable ED50 values of SCT800 and Xyntha in the tail bleeding model: 14.78 and 15.81 IU/kg for bleeding time, respectively; 13.50 and 13.58 IU/kg for blood loss, respectively. " 03/01/2016 - "For pharmacodynamics study, dose-response curves of SCT800 and Xyntha (1-200 IU/kg) were constructed using a tail bleeding model monitoring both bleeding time and blood loss. " 12/01/2003 - "Hemostasis was achieved with a single dose of Kogenate in 94.8% of the 951 bleeding episodes recorded in the study. "
3.	von Willebrand Diseases (von Willebrand's Disease) 01/01/1998 - "In a pharmacokinetic study with Humate-P including six patients with various types of von Willebrand disease, a median half-life of 11.3 h for vWF:RCoF and of 15.2 h for vWF:Ag was found. " 11/01/2011 - "Thrombelastograph platelet mapping in a patient with von Willebrand disease who was treated with Humate-P." 01/01/1998 - "Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease." 05/01/1990 - "Correction of prolonged bleeding time in von Willebrand's disease with Humate-P." 09/01/1988 - "Humate-P for treatment of von Willebrand disease."
4.	Type 3 von Willebrand Disease 01/01/2023 - "The PK and PK/PD models for pdVWF/FVIII were based on data from the phase 1 study (NCT00816660) in patients with type 3 VWD who received either rVWF plus recombinant FVIII (rFVIII, octocog alfa, ADVATE®, Takeda Pharmaceuticals USA, Lexington, MA, USA) or pdVWF/FVIII. " 09/18/2017 - "Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies." 07/02/2011 - "We report a case of von Willebrand disease type 3 with spontaneous iliopsoas hematoma associated with femoral nerve palsy that was well managed with Humate-P treatment." 07/02/2011 - "We describe the case of a patient with von Willebrand disease type 3 with a large iliopsoas hematoma who was treated with a von Willebrand factor concentrate (Humate-P). "
5.	Metrorrhagia (Spotting) 01/01/2005 - "Octocog alfa-PFM is structurally and functionally very similar to a previously marketed, albumin-containing formulation of the same recombinant factor VIII. The haemostatic efficacy of octocog alfa-PFM was rated excellent or good in the acute treatment of most breakthrough bleeding episodes in adolescents or adults with moderately severe or severe haemophilia A who were receiving prophylaxis with octocog alfa-PFM and who had been previously treated with factor VIII. Most bleeding episodes resolved after one or two infusions of octocog alfa-PFM. "

Related Drugs and Biologics

1.	Factor VIII (Coagulation Factor VIII)
2.	human F8 protein
3.	Serum Albumin
4.	von Willebrand Factor
5.	sugar formulated recombinant FVIII
6.	Sucrose (Saccharose)
7.	von Willebrand factor drug combination factor VIII
8.	6-pyruvoyltetrahydropterin synthase (PTPS)
9.	recombinant factor VIII N8
10.	Isoantibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Operative Surgical Procedures
3.	Tooth Extraction (Tooth Extractions)
4.	Intravenous Infusions
5.	Donor Selection